COVID-19 Funding Opportunities

Updated 5/14/2020; 8:45 am

There are a number of funding opportunities offered by federal and non-federal sources for COVID-19 research. For questions about Pivot, please contact Pivot-Help@columbia.edu. For questions about this webpage, contact Stephanie Scott.

    Digestive Diseases Research Center Pilot Grants

    Hereby we announce a new funding opportunity from the Columbia Digestive and Liver Disease Research Center. We anticipate funding two pilot grants annually at $25,000 each. This funding opportunity is open to junior investigators who have not yet obtained NIH R01 funding or equivalent.

    Letter of Intent (LOI). Applicants should submit a letter of intent by May 22, 2020. The LOI needs to include: 1. A brief description of the proposed research (<250 words); 2. A statement of how the applicant meets the eligibility criteria (<150 words); 3. An NIH biosketch. The LOI should be emailed to Seetha Srinivasan (svs2113@cumc.columbia.edu). LOIs will be evaluated, and applicants notified if their LOI was selected to proceed to full applications, by June 1, 2020

    Budget. $25,000 for the duration of one year. Funds can be used for salary support or research expenses, but not for purchasing equipment or for travel.

    Eligibility. Applicants must be junior faculty (Instructors, Assistant Professors and, in specific circumstances, Associate Research Scientists), who have already established or plan to establish an independent research group at CUIMC or CU. Women and underrepresented minorities are particularly encouraged to apply. Applicants should have not yet received NIH R01 funding or equivalent.

    Research areas. All areas of gastrointestinal, pancreatic and liver biology and pathophysiology are eligible for this proposal. Proposals should not, however, focus solely on cancer. Basic and clinical research projects that focus on SARS-CoV-2 are encouraged.

    Application format and deadline.  Applications should adhere to a modified NIH format (0.5 inch margins, single spaced, Arial 11 font) with an Aims page and a 4 page research plan consisting of Background & Significance, Innovation and Experimental Approach. Rigor and sex as a biological variable should be briefly addressed, and it is expected that the proposal will include a section on pitfalls and alternative approaches. The proposal should contain a cover letter (1 page), an abstract (30 lines max, according to NIH standards), an NIH formatted biosketch of the PI, a Budget and Budget Justification section (recommended 1 page, max 2 pages), References (no limit) and a research facilities section. Up to three letters of support may be included. For research that includes vertebrate animals or human subjects, a Vertebrate Animals section or Human Subjects section needs to be included in the application according to NIH format, with IACUC or IRB approval date or pending date. Applications should adhere to the following order: Cover letter, Abstract, NIH Biosketch, Specific Aims, Research Plan, Budget and Budget Justification, Research Facilities, Vertebrate Animals section (max 2 pages), if applicable,   Human Subjects section (max 2 pages), if applicable and Letters of Support (max 3). Applications should contain a header with the title and name of the PI as well as a footer with page numbers. The deadline for submitting applications will be July 1, 2020. Applications should be submitted by email to Seetha Srinivasan (svs2113@cumc.columbia.edu) as single pdf (not exceeding 5MB).

    Review and notification of funding. Proposals will be reviewed by a committee consisting of internal and external reviewers. Funding decisions will be announced by August, 2020.

    Contact. For additional questions, please contact Kara Gross Margolis (kjg2133@cumc.columbia.edu) and Utpal Pajvani (up2104@cumc.columbia.edu).

    Pivot a funding opportunity database. To view COVID-19 funding opportunities or receive emails alerts of new opportunities, click on these instructions where you will be able to:

    For more information about Pivot, click here or contact Pivot-Help@columbia.edu.

    Easily download highlighted COVID-19 opportunities, including global sponsors, a courtesy from Pivot (updated weekly):

    Per InfoEd, "InfoEd Global is proud to be able to share this library of COVID-19 funding opportunities and resources with our colleagues in the research realm and the broader community at large."

    https://www.infoedglobal.com/COVID19/COVID-19

    Go to https://www.grantforward.com/grant-covid# for this free listing, courtesy of GrantForward.

    From GrantForward:

    Regarding COVID-19 / Coronavirus Situation

    As the COVID-19 situation continues to develop, it’s critically important that researchers, who are learning about the virus and pursuing science-based solutions to the global coronavirus pandemic, can find the funding they need. With this in mind, GrantForward is proud to provide free access to a list of funding opportunities in the area of COVID-19.

    The list of available coronavirus-related funding calls and other support for researchers, non-profit organizations and commercial organizations, with all relevant information, will be updated on a daily basis.

    COVID-19’s impacts are reaching every corner of the world. We must stand together. By raising awareness of these funding sources, we are honored to do our part to help researchers expand their scholarly efforts to understand and contend with this global pandemic. If you are aware of other COVID-19 research grants, we would appreciate you sharing them with us. Click here to send us an email.

    All COVID-19 NIH Funding Opportunities are posted on their dedicated COVID-19 website.

    Additional RFA Specific to COVID-19

    • ​​RFA-AI-20-028: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)  - application due date June 29, 2020

    See Mike Lauer blog dated 4/13/2020 with updates about the competing revisions and NOSIs: https://nexus.od.nih.gov/all/2020/04/13/covid-19-funding-and-funding-opportunities/

    Administrative supplements for unanticipated costs:

    NOT-OD-20-086 and NOT-OD-20-087 - If unanticipated costs are identified due to impacts of COVID-19, and unobligated balances are not available to rebudget, recipients may request administrative supplements from the funding ICs (see PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). 

    However, per NIH:

    "While Institutes and Centers plan, based on availability of funding, to issue administrative supplements when absolutely necessary, it is clear that for the vast majority of grantees, supplement requests in the next 2-3 months would be premature. We therefore recommend that institutions hold off on submitting COVID19-related administrative supplement requests until such time as (1) the full impacts of the pandemic on your research are clear, and (2) you have had the chance to discuss the various options with the relevant NIH staff and you have agreed that an administrative supplement is the best option for your project.

    There are two exceptions. The exceptions to this recommendation are for (1) supplements to existing projects that will allow investigators to immediately address scientific questions of direct relevance to the COVID19 epidemic, and (2) supplements that are needed to address immediate, mission critical needs over the next 3 months. Investigators who believe they meet these exceptions should raise these issues with their program officers or grants management specialists prior to submitting such requests."

    NSF - RAPID Research on Coronavirus (COVID-19)

    See https://www.nsf.gov/news/special_reports/coronavirus/ for the Dear Colleague Letters and FAQs on this opportunity.

    Peer Reviewed Medical Research Program (PRMRP) open to Emerging Viral Diseases and Respiratory Health with a focus on COVID-19

    The following opportunities can be found at https://cdmrp.army.mil/funding/prmrp

    Clinical Trial Award (W81XWH-20-PRMRP-CTA-COV)

    Investigator Initiated Research Award (W81XWH-20-PRMRP-IIRA-COV)

    Technology/Therapeutic Development Award (W81XWH-20-PRMRP-TTDA-COV)

    See https://www.pcori.org/funding-opportunities/announcement/covid-19-targeted-pfa

    Deadline: May 26, 2020

    Small Studies: up to $2,500,000 — Large Studies: up to $5,000,000

    DOE Dear Colleague Letter -- Coronavirus Disease 2019 (COVID-19) - Asking for input on COVID-19 rapid research response involving DOE user facilities and infrastructure.

    See https://professional.diabetes.org/content/targeted-rfas

    The expedited application deadline will be 5pm ET on May 22, 2020 for July 1, 2020 funding.

    See full details at: https://standtogether.org/2020/03/17/fresh-ideas-to-combat-covid-19-could-earn-funding/

    Emergent Ventures, the Mercatus Center’s philanthropy project, is offering:

    • $500,000 and $200,000 prizes for the best efforts to find a good treatment rapidly
    • $100,000 for best innovation in social distancing
    • $100,000 for most important innovation or improvement for India
    • $100,000 for the best blog or social media tracking/analysis of the virus
    • $50,000 for the best investigative journalism on coronavirus
    • $50,000 for best coronavirus policy writing

    There is no application process for the prizes. Emergent Ventures will make awards when it sees a significant success.

    Additionally, anyone can apply for fast-tracked grant funding for COVID-19 projects through the Emergent Ventures portal.

    Dimitra Koutsantoni is available to support applicants with their submissions. Her contact info:

    Dimitra Koutsantoni, PhD

    Director of University Corporate, Foundation Relations

    Email: dk2617@columbia.edu

    Call for Rapid Access Proposals for COVID-19 Research

    https://snsapp1.sns.ornl.gov/xprod_ro/f?p=109:26

    With the continuing spread of the COVID-19 pandemic, the Department of Energy Basic Energy Sciences neutron sources will provide remote rapid access to support research into the COVID-19 virus and the search for effective diagnostics and therapies. Beamlines that will be made available at the Spallation Neutron Source (SNS) and High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory, include neutron macromolecular crystallography, small angle scattering, reflectometry, spectroscopy and imaging beamlines.


    SNS and HFIR beamlines are supported by staff with expertise in neutron structural biology, biophysics, chemistry, and nanoscale materials science and engineering and could be used to help to develop physical, chemical and environmental controls to virus transmission, infection and replication, and guide in the development of new diagnostics and therapeutics of disease.  

    Researchers who would like to use these resources should submit a short rapid access proposal, outlining experiment aims and scope, at https://snsapp1.sns.ornl.gov/xprod_ro/f?p=109:26. A facility scientist will contact you regarding your proposal within 2 days. Scientific and technical questions should be sent to Dean Myles at mylesda@ornl.gov